HEALTH TECHNOLOGY

Medtronic receives FDA clearance for next-generation UNiD™ Spine Analyzer with degenerative spine surgery predictive model

Medtronic | July 15, 2022 | Read time : 2 min

Medtronic receives

Medtronic plc a global leader in healthcare technology, announced it has received U.S. Food and Drug Administration clearance for its UNiD™ Spine Analyzer v4.0 planning platform, which includes a new Degen Algorithm for degenerative spine procedures. The algorithm leverages machine learning to help surgeons plan and personalize procedures for patients undergoing lower lumbar spine surgery and predicts spinal compensation mechanisms six months after the operation.

This new update also includes enhancements to the pediatric and adult deformity algorithms predicting compensatory changes to the spine. Medtronic is the first and only company to have FDA cleared predictive models for spine surgery.

The release comes with a new UNiD™ Hub patient-centric platform that enables surgeons to track patients throughout the perioperative care pathway and assess surgical results through long-term radiographic and patient-reported outcomes data collection.

"Patient by patient, our UNiD™ Lab engineers have learned from more than 10,000 spine surgery cases to deliver greater insights to surgeons that lead to better patient alignment. It is truly exciting to share that we have expanded our UNiD™ ASI technology to include hardware and software solutions dedicated to helping spine surgeons treat degenerative spinal pathologies, where the majority of spine surgery is performed."

Dan Wolf, vice president and general manager, intelligent Data Solutions within the Cranial & Spinal Technology business, which is part of the Neuroscience Portfolio at Medtronic

Degenerative spine disease is a common health condition and significant cause of disability for many patients worldwide1. The UNiD™ ASI Degen Algorithm helps surgeons achieve spinal alignment by more accurately planning procedures and predicting spinal alignment after six months.

Surgical planning, using the UNiD Spine Analyzer, is especially important for degenerative spine procedures, as studies suggest nearly a third of these degenerative patients have a hidden deformity2. A study suggests that when sagittal alignment is not achieved during these procedures, patients are at 10 times greater risk of experiencing degeneration of discs above or below the level where the operation was performed3 Moreover a study shows that 62% of patients remained sagittally malaligned after their procedure,4 which may lead to revision surgery3,5.

"Alignment matters for all spinal surgery – both short construct degen and long construct deformity cases," said Dr. Christopher Kleck, an orthopedic spine surgeon at the University of Colorado. "Planning all of these cases with my UNiD Lab engineer ensures that my surgical plan is backed by artificial intelligence and clinically important predictive models to set my patients up for long-term success."

This new technology further demonstrates Medtronic's commitment to offering solutions for all spinal pathologies, including deformity and degenerative conditions.  Over time, UNiD ASI technology will continue to evolve as more case data is added and predictive algorithms are further refined to help make spine surgery more predictable for surgeons and patients alike.

About UNiD ASI Platform
The UNiD ASI platform uses a database of more than 10,000 surgical cases to power algorithms that visualize multiple permutations, allowing surgeons to better understand their patient's alignment before surgery, customize a surgical plan and use patient-specific rods to help ensure the goals of the surgery are achieved. AI helps visualize mechanisms above and below the spine that will most likely occur based on the surgical plan in order to enhance clinical and surgical workflow and increase reproducibility.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary.

Spotlight

Sutter Health is one of the nation's leading not-for-profit healthcare networks, which includes award-winning physician organizations, acute care hospitals, surgery centers, medical research facilities and specialty services.

Spotlight

Sutter Health is one of the nation's leading not-for-profit healthcare networks, which includes award-winning physician organizations, acute care hospitals, surgery centers, medical research facilities and specialty services.

Related News

HEALTH TECHNOLOGY

Trukera™ Medical Launches New ScoutPro™ Osmolarity System

Trukera Medical | September 13, 2022

Trukera™ Medical last week announced a corporate rebranding to reflect thea company’s expanded vision and strategic growth plans targeting broader unmet needs in corneal health. Trukera Medical unveiled the first product under the new company name, the ScoutPro™ Osmolarity System. Designed to help advance corneal health decisions for today’s busy eye care practices, ScoutPro is the first and only portable osmometer in the U.S. “The ScoutPro Osmolarity System is an exciting technology developed around the evolving needs of today’s eye care professionals. Premium cataract and refractive practices are now the fastest growing adopters of osmolarity testing, given the prevalence of hyperosmolarity in their patient demographics and the risk it poses to compromising corneal cell health and driving refractive instability. More than ever, these practices require patient care solutions that can seamlessly adapt into established operational models, not the other way around, to deliver a premium patient experience, efficiency of care, and minimize staff time and disruptions. We’re proud to bring a solution to market addressing these needs, and to help more practices objectively identify and manage such a critical component to patient’s corneal health and refractive outcomes.” Adam Szaronos, Trukera Medical CEO The ScoutPro Osmolarity System brings together nanoliter volume sample collection and analysis in a single portable device. Users can now bring laboratory testing to patients anywhere in the practice to quickly test and provide objective results in the palm of their hand. The system is built upon the company’s established accuracy trusted in over 24 million tests globally to date, with an industry-leading precision. “Toxic hyperosmolarity damages sensitive corneal nerves and may cause refractive instability. As cornea and cataract/refractive specialists, we are cognizant of the importance of this to our surgical outcomes and the overall health of our patients’ eyes. ScoutPro gives us the ability to precisely determine osmolarity quickly and easily, without disrupting patient flow,” said Dr. Lisa Nijm, Chief Medical Advisor for Ophthalmology at Trukera Medical and Corneal Surgeon at Warrenville Eye Care and LASIK Center in Illinois. The ScoutPro Osmolarity System is now available for pre-order in the U.S. and will be commercially launched at the upcoming World Cornea Congress and the American Academy of Ophthalmology later this month. About Trukera Medical Trukera Medical is a global leader in developing and marketing comprehensive corneal health technologies. The company introduced tear osmolarity testing to eye care with its flagship device, the TearLab Osmolarity System, which has been used over 24 million times worldwide. Trukera Medical’s expanding portfolio includes ScoutPro, the first and only portable osmolarity system in the U.S. The company’s dedicated focus is improving corneal health, both as a primary goal and in preparation for surgery.

Read More

HEALTH TECHNOLOGY

IQVIA Decentralized Clinical Trial Program Achieves Independent GDPR Validation

IQVIA | September 29, 2022

IQVIA a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry announced its Decentralized Clinical Trial (DCT) program has received GDPR compliance validation from TRUSTArc. This marks the first instance of a DCT service receiving this European data privacy validation. TRUSTArc’s third-party validation demonstrates that IQVIA’s DCT program processes personal data in accordance with GDPR, allowing customers to address participant and investigator privacy concerns that may arise because of their participation in decentralized trials. “At IQVIA, we are committed to delivering decentralized studies, we recognize the criticality of patient data protection in doing this and we understand the focus on data protection by European regulators,” said Ronan Brown, SVP and head of Patient Centric Solutions & Decentralized Trials. “IQVIA is proud to have this validation prove our longstanding dedication to data protection in decentralized trials.” TRUSTArc maps it’s GDPR Validation requirements to applicable GDPR Articles and ISO 27001 standards, alongside the standards of it’s own Privacy and Data Governance Accountability Framework. This validation is yet another step IQVIA has taken to enable DCTs to be brought to a wider group of participants, improving diversity, sustainability, and trust in clinical development. “Achieving a GDPR validation demonstrates IQVIA’s commitment to ensuring the highest standards of delivering decentralized studies to the people it serves. Organizations of all sizes must become privacy-forward to earn the trust of their customers. IQVIA has consistently prioritized being privacy-forward to earn the trust of their customers and the TRUSTArc GDPR and CCPA Validations reinforce that standing.” Chris Babel, CEO, TRUSTArc About IQVIA IQVIA is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 82,000 employees, IQVIA conducts operations in more than 100 countries. IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors, and scientific advances, in an effort to advance their path toward cures.

Read More

HEALTH TECHNOLOGY

Viveon Health Acquisition Corp. Announces Filing of Registration Statement on Form S-4 in Connection with Suneva Medical

Viveon Health Acquisition Corp. | July 16, 2022

Viveon Health Acquisition Corp. a special purpose acquisition company, and Suneva Medical, Inc. an innovative medical technology company using regenerative medicine to change the standard of care in aesthetic treatments, announced that VHAQ filed a registration statement on Form S-4 with the U.S. Securities and Exchange Commission on July 13, 2022. The Registration Statement, contains a preliminary proxy statement/prospectus in connection with the previously announced business combination between VHAQ and Suneva. While the information within the Registration Statement is subject to change, it provides important information about Suneva Medical and VHAQ, as well as the proposed business combination. On January 12, 2022, VHAQ entered into a merger agreement with Suneva. The combined company is expected to be listed on the NYSE American upon completion of the transaction, which is expected to occur in the second half of 2022, subject to approval by VHAQ’s shareholders, the Registration Statement being declared effective by the SEC, and other customary closing conditions. Included in the Registration Statement are Suneva’s financial results for 2021 and for the first quarter of 2022. Overall, Suneva delivered strong revenue growth in 2021 and generated $29.5 million of net sales and $6.3 million in Q1 of 2022. Suneva’s full financial results and related disclosures can be found in the Registration Statement. About Suneva Medical, Inc. Suneva Medical, Inc., headquartered in San Diego, CA, is a leader in regenerative aesthetics. It is focused on developing, manufacturing and commercializing branded products for providers and their patients. Suneva offers a portfolio of products to address the impact of the aging process to deliver solutions that leverage the body’s own restorative capacity. The product portfolio is composed of several “only” and “first to market” solutions with both FDA PMA approval and 510(k) clearance. About Viveon Health Acquisition Corp. Viveon Health Acquisition Corp. is a blank check company, also commonly referred to as a special purpose acquisition company, or SPAC, formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

Read More